Bronchodilator effects of caffeine in coffee. A dose-response study of asthmatic subjects.
Although caffeine is a universal drug and has multiple pharmacologic and physiologic actions in man, there are surprisingly few objective data about its effect on pulmonary function. We conducted a short-term, double-blind, randomized crossover study in nine asthmatic adults who ingested decaffeinated coffee containing varying amounts of added caffeine (mean of 0.2,2.5,5.6, and 7.2 mg/kg of body weight) on different days. The subjects also ingested decaffeinated coffee and aminophylline (200 mg) on a separate day of study. Baseline and post-drug determinations of serum levels of caffeine and theophylline, forced expired volume and flow, specific airway conductance (Gaw/VL), vital signs, and reported symptoms were obtained. Peak increases in serum caffeine concentrations (mean, 12.4 micrograms/ml +/- 1.5 micrograms/ml) occurred 45 minutes following the highest dose of caffeine (7.2 mg/kg), whereas the peak theophylline level (mean 3.8 micrograms/ml +/- 0.4 micrograms/ml) occurred 90 minutes following oral administration of aminophylline (mean theophylline, 2.6 mg/kg). Comparable peak increases in the forced expiratory volume in one second (FEV1), the forced expiratory flow during the middle half of the forced vital capacity (FEF25-75%), and Gaw/VL occurred at 120 minutes following aminophylline and the highest dose of caffeine, indicating that caffeine is an effective bronchodilator but is only 40 percent as active as an equivalent molar dose of theophylline. Regression analysis revealed statistically significant dose-response relationships between peak increases in serum caffeine concentrations and increases in FEV1, FEF25-75%, and Gaw/VL from baseline values. These findings have diagnostic and therapeutic implications regarding the use of caffeine prior to tests of pulmonary function and as a dietary agent, alone or in combination with theophylline.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000628:Aminophylline / Q000008:administration & dosage; D001249:Asthma / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D002110:Caffeine / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D003069:Coffee; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012123:Pulmonary Ventilation; D011897:Random Allocation; D014797:Vital Capacity; D014970:Xanthines / Q000097:blood
D001993:Bronchodilator Agents; D003069:Coffee; D014970:Xanthines; D000628:Aminophylline; C008514:methylxanthine; D002110:Caffeine